CD1D and Miyoshi myopathy: To determine in vivo antitumor efficacy, we established disseminated AML and MM models via intravenous (i.v.)injection of MOLM-13 and MM.1s.CD1d in immunodeficient NOD scid gamma (NSG) mice.